Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docosahexaenoic acid (Hospital de la Santa Creu i Sant Pau Research Institute)
- Development stage
- Unknown
- Lead developer
- Hospital de la Santa Creu i Sant Pau Research Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Docosahexaenoic acid (DHA) is a long-chain omega-3 polyunsaturated fatty acid being investigated by the Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau for the treatment of metabolic complications in HIV-infected patients. Specifically, it targets hypertriglyceridemia, hypercholesterolemia, and lipodystrophy associated with highly active antiretroviral therapy (HAART). DHA acts as an agonist of the nuclear receptor Peroxisome Proliferator-Activated Receptor gamma (PPAR-gamma), which promotes adipocyte differentiation and modulates lipid metabolism. It also exhibits anti-inflammatory properties, potentially reducing TNF-alpha levels. In clinical trials, high-dose DHA (4g daily) significantly reduced triglyceride levels in patients on combination antiretroviral therapy.
- Brand names
- Pro-Mind
- Other names
- DHAcis-4,7,10,13,16,19-docosahexaenoic acid22:6n-3
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on docosahexaenoic acid (Hospital de la Santa Creu i Sant Pau Research Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docosahexaenoic acid (Hospital de la Santa Creu i Sant Pau Research Institute).